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Abstract
Background: Recently, a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been developed
as an international and standardized brief cognitive test, which is easily performed in everyday clinical practice for
neuropsychological assessment in multiple sclerosis (MS). However, we need to gather more information about this
tool compared to other neuropsychological batteries. The aim of our study is to compare the performance of BICAMS
and Brief Repeatable Battery (BRB) in MS subjects.
Methods: Tests of the BRB and BICAMS were administered to MS patients recruited from 11 Italian MS centres.
Cognitive impairment (CI) was defined as the failure on at least two tests (scores below the fifth percentile) on
the BRB and as the failure on at least one test of the BICAMS. The agreement between the performances on the
two batteries was assessed through Cohen’s K statistic. Finally we calculated the effects sizes for each test of the
two batteries using Cohen’s d.
Results: The two batteries were administered to 192 MS patients (142 women, 50 men; mean age 41.4 ± 10.8 years,
mean education 12.3 ± 3.5 years). Mean scores of patients were lower compared to those of healthy subjects in all the
cognitive measures examined. Forty-six MS patients were identified as impaired and 48 as unimpaired on both of the
batteries, when the Symbol Digit Modalities Test (SDMT) was included in the analysis. Cohen’s K statistic was 0.46
which corresponds to a moderate accord. If the SDMT was excluded from the BRB, 37 MS patients were identified as
impaired and 57 as unimpaired on both of the batteries. Cohen’s K statistic was 0.3 which corresponds to a poor
accord. The SDMT, the Paced Auditory Serial Addition Test (PASAT) 3 and 2 yielded higher d values (SDMT 0.83, PASAT
3 0.65, PASAT 2 0.84).
Conclusions: This study confirms the feasibility of BICAMS in everyday clinical practice for the identification of CI and
highlights the good psychometric properties of the SDMT.
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Background
Cognitive impairment (CI) affects about 40–60 % of
multiple sclerosis (MS) subjects [1]. It involves all the
disease subtypes and it can be documented from the
very beginning of the disease [1, 2]. Once established, it
tends to progress over time, sometimes independently
from the accumulation of physical disability [1]. Deficits
of complex attention, information processing speed, epi-
sodic memory and executive functioning are prominent,
whereas language and general intelligence are usually
spared [3]. Also independently of physical disability, CI
can have an important negative impact on patient
performance in everyday activities, employment, social
and recreational activities [1]. For this purpose, assess-
ment of MS-related CI is strongly recommended. The
most commonly used instrument to estimate cognitive
dysfunction in MS patients, both for clinical practice
and research purposes, is the Brief Repeatable Battery
(BRB), that includes cognitive domains most frequently
affected [4]. Normative values in the Italian population
are available [5]. Despite its good psychometric proper-
ties, the implementation in clinical practice is limited by
its time-consuming nature (about 45 min) and the need
of administration and interpretation by experienced
neuropsychologists. Therefore, there has been consider-
able effort over the past decade to streamline the neuro-
psychological assessment in MS, by developing brief
assessment tools that can be incorporated in everyday
patient assessment. In particular, recently, a Brief Inter-
national Cognitive Assessment for MS (BICAMS) has
been recommended as an international, validated and
standardized brief cognitive test [6]. It is easily per-
formed in everyday clinical practice as it can be com-
pleted in 15 min and can be administered by health care
professionals who are not cognitive specialists. No special
equipment (beyond pen, paper and stopwatch) is required
[6, 7]. Translation and validation of the BICAMS is on
going in several countries. It has been recently validated in
the American [7], Czech [8], Iranian [9] and Italian popu-
lations [10]. We can consider BICAMS as a brief, practical
and universal assessment tool for CI in MS subjects.
However, little is known on its performance in compari-
son to other neuropsychological batteries. For this pur-
pose, the aim of our study is to compare the performance
of BICAMS and BRB as screening tools for cognitive
impairment in MS patients [5, 10].
Methods
A total of 192 MS patients (142 women; 50 men), among
those consecutively admitted to some of the major
Italian MS centres (Bari, Barletta, Bologna, Cagliari,
Chieti, Florence, Gallarate, Lanciano, Milan, Naples and
Rome), were recruited. Inclusion criteria were diagnosis
of relapsing-remitting (RR) MS [11] and age >18 years.
Inclusion was restricted to RRMS subjects in order to
avoid heterogeneity of cognitive profile due to MS
course. Exclusion criteria were presence of current or
past neurological disorder other than MS, major psychi-
atric illness, history of learning disability, serious head
trauma, alcohol or drug abuse and relapse and/or cor-
ticosteroid use within 4 weeks preceding assessment. All
the subjects had adequate vision and hearing to undergo
the tests. All the participants in the study provided their
informed consent and the study was approved by the
ethic committee of the University of Florence.
Neuropsychological test procedures
At each site, patients were examined by the same neuro-
psychologist, who had participated to a common training
session, in order to ensure uniform administration, data
recording and scoring procedures. Tests of the BRB and
BICAMS were administered in a standardized manner,
during daytime, in a quiet room, and in a fixed order.
We first administered the BRB and subsequently the
BICAMS, in different sessions, within 1 week. The
SDMT [4] was given only once. We used the validated
Italian translation of both batteries [5, 10]. The BRB
incorporates tests of verbal memory acquisition and
delayed recall (Selective Reminding Test- SRT), visual
memory acquisition and delayed recall (10/36 Spatial
Recall Test-SPART), attention, concentration and speed
of information processing (Paced Auditory Serial
Addition Test –PASAT; SDMT) and verbal fluency on
semantic stimulus (Word List Generation-WLG) [4].
The administration of the whole BRB battery takes about
45 min. The BICAMS includes the SDMT [4], California
Verbal Learning Test, second edition (CVLT-II) first five
trials, for assessing verbal memory [12] and Brief Visuo-
spatial Memory Test-Revised (BVMT-R) first three recall
trials, for visual-spatial memory [13]. Administration of
the whole battery takes about 15 min.
Statistical analysis
Group comparisons were assessed through Student’s t
test, Mann–Whitney U test and χ2 test, as appropriate.
CI was defined as the failure on at least two tests (scores
below the fifth percentile) on the BRB, based on the
Italian normative data [5]. Failure on the BICAMS was
defined as the failure in at least one test of the battery
[10]. Performance on the SDMT was assessed using
normative data from the Italian BICAMS validation [10].
The agreement between the performances of the two
batteries was assessed through Cohen’s K statistic [14–16].
The sensitivity, specificity and accuracy of the BICAMS
against the BRB were assessed. Finally we calculated the
effects sizes for each test of the two batteries using
Cohen’s d (difference between means divided by pooled
SD) separating MS patients and controls [17].
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Results
The study sample consisted of 192 consecutive RRMS
patients from 11 Italian MS Centres (Table 1). Table 2
shows mean scores of patients and normative samples
on the neuropsychological tests [5, 10]. Mean scores of
patients were lower compared to those of healthy
subjects in all the cognitive measures examined. To
compare the performance on the BICAMS and the BRB,
we have repeated the analysis excluding SDMT, which
was the only neuropsychological test included in both of
the batteries. This exclusion is intended to avoid an
overestimation of the accord between the two assess-
ment tools. Forty-six MS patients were identified as
impaired and 48 as unimpaired on both batteries, when
the SDMT was included in the analysis. Cohen’s K
statistic was 0.46 which corresponds to a moderate
accord [14–16]. The Cohen’s K statistic estimating the
agreement between the SDMT alone and the BRB was
comparable (0.42). As expected, the concordance
decreased if we excluded the SDMT from the BRB. In
this case, 37 MS patients were identified as impaired and
57 as unimpaired on both of the batteries. Cohen’s K
statistic was 0,3 (0.26 for the SDMT alone) which corre-
sponds to a poor accord [14–16]. Using the whole BRB
as the gold standard, overall BICAMS sensitivity was
58,2 %, specificity 86,7 %, with an accuracy of 75 %.
Using the SDMT alone the sensitivity was 43 %, the
specificity 95,6 % and accuracy 73,9 %. Table 3 shows
Cohen’s d for different tests [17]. Overall, verbal memory
tests of the BRB and BICAMS were comparable (SRT-LTS
0.55, SRT-CLTR 0.61, CVLT 2 0.61). Instead, the BVMT-R
of the BICAMS showed a higher d value (0.60) as
compared with the SPART test (0.38). Finally, the SDMT,
PASAT 3 and 2 yielded higher d values (SDMT 0.83,
PASAT 3 0.65, PASAT 2 0.84).
Discussion
Cognitive assessment represents a key step in taking
charge of MS patients. The most widely used neuro-
psychological battery is BRB [5]. Recently the BICAMS,
a rapid tool, more suitable to be incorporated in every-
day patient assessment, has been developed [6]. We
Table 1 Characteristics of the study sample (# 192 MS subjects)
Age, years, mean (SD) 41.4 (10.8)
Education, years, mean (SD) 12.3 (3.5)
Gender (women, men) 142/50
Disease duration, years, mean (SD) 12.7 (8.9)
EDSS, mean (SD) 2.7 (1.7)
# of relapses in the year prior to inclusion, mean (SD) 0.5 (0.8)
Treatment with DMD, n (%) 154 (80.2)
MS multiple sclerosis, SD standard deviations, EDSS expanded disability status
scale, DMD disease modifying drugs
Table 2 Mean scores (SD) of patients and normative samples
on the neuropsychological tests [5, 10]
Test MS (#192) HC p
BRB
SRT-LTS 39.9 (14.4) 47.5 (13.1) <0.001
SRT-CLRT 31.3 (15.0) 40.3 (14.4) <0.001
SPART 18.9 (5.5) 20.9 (4.9) <0.001
PASAT-3 36.1 (15.7) 45.0 (10.6) <0.001
PASAT-2 25.6 (14.1) 36.5 (11.5) <0.001
SRT-D 7.9 (2.9) 8.9 (2.2) <0.001
SPART-D 6.4 (2.4) 7.2 (2.4) 0.002
WLG 23.4 (6.7) 26.1 (5.8) <0.001
BICAMS
SDMT 46.4 (12.8) 56.3 (11.3) <0.001
CVLT-II 49.9 (12.1) 56.3 (9.0) <0.001
BVMT-R 23.7 (8.0) 27.9 (6.1) <0.001
MS multiple sclerosis, HC healthy control, BRB brief repeatable battery, SRT-LTS
selective reminding test-long term storage, SRT-CLRT selective reminding
test-consistent long term retrieval, SPART spatial recall test, PASAT-3 paced
auditory serial addition test-3 s, PASAT-2 paced auditory serial addition test-2 s,
SRT-D selective reminder test-delayed, SPART-D spatial recall test-delayed, WLG
world list generation, BICAMS brief international cognitive assessment in multiple
sclerosis, SDMT symbol digit modalities test, CVLT-II California verbal learning
test-second version, BVMT-R brief visuospatial memory test-revised
Table 3 Cohen’s d for each test of the two batteries separating















BRB brief repeatable battery, SRT-LTS selective reminding test-long term storage,
SRT-CLRT selective reminding test-consistent long term retrieval, SPART spatial
recall test, PASAT-3 paced auditory serial addition test-3 s, PASAT-2 paced auditory
serial addition test-2 s, SRT-D selective reminder test-delayed, SPART-D spatial recall
test-delayed, WLG world list generation, BICAMS brief international cognitive
assessment in multiple sclerosis, SDMT symbol digit modalities test, CVLT-II
California verbal learning test-second version, BVMT-R brief visuospatial
memory test-revised
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recently published normative values for the BICAMS in
the Italian population [10]. The implementation of
BICAMS is still in its infancy; therefore we need to
obtain more information about its performance in com-
parison to other neuropsychological batteries. In the
present study we administered to MS patients both the
BRB and the BICAMS. Mean scores of patients were
lower compared to those of healthy subjects [5, 10] in all
the cognitive measures examined. This is in line with
the typical cognitive profile in MS patients [1]. In our
study, tests with higher discriminating ability according
to the d values were the SDMT, PASAT 2 and 3 s. This
finding is in line with recent literature, identifying the
SDMT as the test with higher ability in differentiating
MS patients from healthy controls [18, 19]. On the basis
of our results, the agreement between the BICAMS and
the BRB is fair to moderate and mainly dependent on
the inclusion of the SDMT, which is the only common
test between the two batteries. We can hypothesize that
the BICAMS and the BRB cannot be considered as
equivalent in the assessment of CI in MS. The BRB
investigates more comprehensively the cognitive profile,
including wider assessment than the BICAMS. There-
fore, we can consider the BRB a brief neuropsychological
battery more complete than the BICAMS and more suit-
able to identify change over time [20–22]. The BICAMS,
on the other hand, can represent a valid alternative to a
more comprehensive battery when available resources
are scarce. Since in our study cognitive evaluations were
performed by neuropsychologists, further analyses includ-
ing the administration of tests by health care professionals
who are not cognitive specialists are needed, in order to
confirm the external validity of our findings.
Conclusions
In conclusion, on the basis of our results, we can con-
sider the BICAMS a brief and feasible tool appropriate
for the cognitive assessment of MS patients and for re-
search use. It seems important to stress that, in optimal
clinical conditions, where a neuropsychologist can take
care of the cognitive assessment, it is preferable to
achieve a more thorough cognitive evaluation using tools
including neuropsychological tests that investigate sev-
eral cognitive domains impaired in MS.
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